KALV vs. APLT, VERV, ATXS, YMAB, AVTE, ABUS, IGMS, TVTX, LRMR, and ALT
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Applied Therapeutics (APLT), Verve Therapeutics (VERV), Astria Therapeutics (ATXS), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), Travere Therapeutics (TVTX), Larimar Therapeutics (LRMR), and Altimmune (ALT). These companies are all part of the "pharmaceutical preparations" industry.
KalVista Pharmaceuticals (NASDAQ:KALV) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
98.3% of Applied Therapeutics shares are owned by institutional investors. 12.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
KalVista Pharmaceuticals' return on equity of -86.06% beat Applied Therapeutics' return on equity.
KalVista Pharmaceuticals received 258 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
KalVista Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.
KalVista Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 109.73%. Applied Therapeutics has a consensus price target of $11.00, indicating a potential upside of 161.28%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than KalVista Pharmaceuticals.
KalVista Pharmaceuticals has higher earnings, but lower revenue than Applied Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 3 mentions for Applied Therapeutics and 1 mentions for KalVista Pharmaceuticals. Applied Therapeutics' average media sentiment score of 1.32 beat KalVista Pharmaceuticals' score of 0.59 indicating that Applied Therapeutics is being referred to more favorably in the news media.
Summary
Applied Therapeutics beats KalVista Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
